Page 48 - MemoriaCIBER-2017ENG

Molecular and imaging biomarkers, and precision CV medicine Coordinator: Javier Díez
In the rst few months since Programme 4 of the CIBERCV was got under way, we identi ed which projects already begun by the di erent groups could be useful for the objectives of the Programme and what synergies could be necessary to carry these out, from the methodological standpoint and that of obtaining and common use of resources
Hence, in the case of Line 1 (Evaluation of known biomarkers) a signi cant thrust forward was given to the large-scale validation projects In general terms these projects also need to be undertaken during 2018, since due to the number of patients and number of determinations required, these are medium- extended term projects
As part of the projects in the eld of heart failure, progress has been made as agreed with recruiting and analysis of samples In the following yearly period (2018) we hope to have results of the large-scale validation of biomarkers in this eld (interstitial myocardial brosis, CA125 in patients with cardio-renal syndrome, non-vasomotor e ects of Sacubitril-Valsartan)
In a similar sense, in the eld of the acute coronary syndrome, satisfactory progress is being made with the recruitment and measurement of biomarkers In the following yearly period (2018) we hope to obtain results on a panel of miRNAs for di erential diagnosis of ischaemic cardiomyopathy without coronary obstruction, the usefulness of ApoJ-Gly in early coronary ischaemia and troponin as risk biomarker in acute heart failure
We should lastly add that Domingo Pascual, with the cooperation of the Management of Programme 4, got under way a platform for collecting information on samples and biomarkers available in the CIBERCV: The Platform for Personalised Network Cardiovascular Medicine (PMPcv net), as part of Line 1
In the case of Line 2 (Identi cation of new biomarkers) nosological entities on which to focus e orts have been identi ed Hence, in the eld of heart failure, projects have been identi ed in the elds of HFPEF, HFREF and cardio-oncology, as well as pre-clinical studies The work for this year has already enabled identifying new potential biomarkers such as the IGBP2 or the intraventricular ow in the HFPRF, or the analysis of heart deformation by CMR in the HFREF
In the eld of ischaemic vascular disease, this includes projects on subclinical atherosclerosis, acute coronary syndrome and risk of coronary diseases, as well as other elds (aneurysm of the aorta, auricular brillation, early ageing) The work for this year has already enabled identifying new biomarkers associated with cardiovascular risk as parameters for the structure and composition of the plate or DNA methylation
In the eld of productivity, it should be stressed that in 2017 over 50 collaborative articles were indexed, with an average IF of 9 636 points (JCR), understandably not all of these being in the context of projects under way, since these have recently been started The members of Programme 4 have furthermore produced two patents (F Sánchez-Madrid and D Pascual) and a spin-o (L Badimón) and have obtained nancing in national (V Andrés, J Cinca, M Rivera, J Díez) and European projects (V Andrés, J Díez)
48 CIBER ANNUAL REPORT 2017